AUROPHARMA2023-01-012023-03-31 AUROPHARMA2023-01-012023-03-31 AUROPHARMA2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2023-01-012023-03-31in-bse-fin:OneOperatingExpenses02Member AUROPHARMA2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member AUROPHARMA2023-01-012023-03-31in-bse-fin:FourOperatingExpenses02Member AUROPHARMA2023-03-31 AUROPHARMA2023-01-012023-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2023-01-012023-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2023-01-012023-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2023-01-012023-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2023-01-012023-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AUROPHARMA2023-01-012023-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524804 AUROPHARMA NA Aurobindo Pharma Limited Equity 2022-04-01 2023-03-31 2023-05-27 2023-05-18 INR Millions Yearly 15:30:00 18:45:00 2023-05-27 2023-05-27 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmacuetical 2023-01-01 2023-03-31 Audited Consolidated 64729600000.00 1349100000.00 66078700000.00 26705700000.00 5887500000.00 -3283500000.00 8519000000.00 556000000.00 3455700000.00 16879100000.00 58719500000.00 7359200000.00 0.00 7359200000.00 5803900000.00 -3562400000.00 2241500000.00 0.00 5117700000.00 0.00 0.00 0.00 -58600000.00 5059100000.00 130800000.00 5189900000.00 5062700000.00 -3600000.00 5193500000.00 -3600000.00 585900000.00 1 8.64 8.64 0.00 0.00 8.64 8.64 1. The above consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on Consolidated financial statements and Ind AS 28 on Investments in Associates and Joint ventures notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended. 3. The above consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 27, 2023. The results for the year ended March 31, 2023 has been audited and for the quarter ended March 31, 2023 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2023 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2023. 4. Exceptional items represent the following items which have been credited/(debited) to consolidated statement of profit and loss. Particulars For the quarter ended For the year ended March 31, 2022 March 31, 2022 Gain on sale of tangible assets * 3.6 1,160.3 Impairment of intangible assets and goodwill ** (681.2) (1,490.0) Impairment of capital work in progress** (950.0) (950.0) Total (1,627.6) (1,279.7) * Gain on sale and lease back of Group's immovable property situated in Dayton, New Jersey, USA. ** Due to uncertain regulatory development and change in business plan impacting the goodwill, intangible assets, capital work in progress relating to certain products, the Group recorded an impairment charge of Rs. 2,440. 5. The Group operates in only one reportable segment viz., 'Pharmaceutical Products'. 6. 'During the year, a) Auro Cure Private Limited, India renamed itself as Eugia Steriles Private Limited, w.e.f. July 26, 2022. b) Wytells Pharma Private Limited, India renamed itself as Eugia SEZ Private Limited, w.e.f. September 2, 2022. c) Auro Medics Pharma LLC, USA renamed itself as Eugia US LLC, w.e.f. August 8, 2022. d) TheraNyM Biologics Private Limited, India was incorporated w.e.f. September 22, 2022. e) PT Aurogen Pharma Indonesia was incorporated w.e.f. July 1, 2022. f) Auro Steriles LLC was dissolved w.e.f September 30, 2022. g) Tergene Biotech Pvt.Ltd, India had become Tergene Biotech Limited w.e.f. October 20, 2022. h) Auro Pharma India Private Limited, India renamed itself as Apitoria Pharma Private limited w.e.f. March 29, 2023. Single segment 2022-04-01 2023-03-31 Audited Consolidated 248553800000.00 2905900000.00 251459700000.00 96525100000.00 20504300000.00 -4096800000.00 35222500000.00 1404800000.00 12445800000.00 63212300000.00 225218000000.00 26241700000.00 0.00 26241700000.00 10714800000.00 -3866300000.00 6848500000.00 0.00 19393200000.00 0.00 0.00 0.00 -116700000.00 19276500000.00 7355800000.00 26632300000.00 19275000000.00 1500000.00 26630800000.00 1500000.00 585900000.00 1 267812600000.00 32.90 32.90 0.00 0.00 32.90 32.90 Foreign exchange loss (net) 0.00 Other Expenses 16879100000.00 Foreign exchange loss (net) 395800000.00 Other Expenses 62816500000.00 120000000.00 79953800000.00 44964000000.00 0.00 5960700000.00 24322400000.00 8936100000.00 0.00 900000000.00 3017400000.00 0.00 55700000.00 1503700000.00 4576800000.00 6774900000.00 7054500000.00 183443200000.00 85112300000.00 1510000000.00 44663800000.00 43962900000.00 16879100000.00 124300000.00 2903500000.00 110043600000.00 756200000.00 19544600000.00 215456700000.00 0.00 0.00 398899900000.00 585900000.00 267812600000.00 268398500000.00 268518500000.00 6189600000.00 3340300000.00 9529900000.00 1727200000.00 3896100000.00 0.00 290400000.00 15443600000.00 42425600000.00 38713100000.00 18245300000.00 99384000000.00 11432500000.00 2005300000.00 2116000000.00 0.00 114937800000.00 0.00 0.00 130381400000.00 398899900000.00 Notes continued........ 7. a) The Board of Directors of the Aurobindo Pharma limited (Holding Company) at its meeting held on March 28, 2022 had approved the acquisition of business including certain assets of Veritaz Healthcare Limited (Veritaz). Consequently the Holding Company entered into a definitive agreement with Veritaz for the said acquisition for total consideration of Rs. 1,710 and obtained control effective April 1, 2022 over such business and assets. b) The Board of Directors of the Holding Company at its meeting held on June 17, 2022 had approved investment in GLS Pharma Limited (GLS) through subscription of 204,819 equity shares for an aggregate consideration of Rs. 93.5 (constituting 17% of the equity share capital of GLS) and acquisition of 409,339 equity shares from the selling shareholders for an aggregate consideration of Rs. 187 (constituting of 34% of equity share capital of GLS). During the quarter ended June 30, 2022, the Holding Company subscribed to 204,819 equity shares of GLS consequent to execution of share subscription and purchase agreement. During the previous quarter on satisfaction of the closing conditions, the Company acquired the additional 409,339 equity shares. Consequent to the above acquisitions, the results of the current quarter/period are strictly not comparable to the previous quarters/periods. 8. During the quarter ended March 31, 2022, the Holding Company elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Holding Company has recognised provision for income tax for the year ended March 31, 2022 and re-measured its deferred tax assets /liabilities based on the rate prescribed in the said Section. The impact of this change has been recognised in the statement of profit and loss during the year ended March 31, 2022. 9. The figures for the current quarter and quarter ended March 31, 2022, are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and March 31, 2022, respectively and published year to date figures up to third quarter ended December 31, 2022 and December 31, 2021, respectively, which were subject to limited review by the statutory auditors. 10. The consolidated financial results of the Group for the quarter and year ended March 31, 2022, were audited by the M/s BSR & Associates LLP, Chartered Accountants, the predecessor auditor, who have expressed an unmodified opinion. 0.00 -9267000000.00 -4321100000.00 0.00 -3549600000.00 0.00 0.00 -2193600000.00 0.00 7076500000.00 0.00 -1240500000.00 0.00 12445800000.00 0.00 217500000.00 0.00 2328000000.00 0.00 -381400000.00 0.00 0.00 0.00 -191400000.00 0.00 0.00 -130100000.00 4174600000.00 0.00 4967700000.00 31209400000.00 0.00 -1289500000.00 -1459000000.00 7172400000.00 0.00 23867500000.00 0.00 1969700000.00 24568500000.00 20141000000.00 0.00 0.00 0.00 0.00 110900000.00 24038000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3166000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1466200000.00 0.00 -16608400000.00 0.00 -39777500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24576100000.00 0.00 0.00 924700000.00 4395300000.00 1112000000.00 0.00 0.00 18144100000.00 2234100000.00 -600000.00 2233500000.00 41689200000.00 43922700000.00 Re-measurement of defined benefit liability 7500000.00 Equity investments through other comprehensive income – net change in fair value 22300000.00 Re-measurement of defined benefit liability 79400000.00 Equity investments through other comprehensive income – net change in fair value -65800000.00 29800000.00 13600000.00 900000.00 19500000.00 Exchange differences on translating the financial statements of foreign operations 101900000.00 Exchange differences on translating the financial statements of foreign operations 7361700000.00 101900000.00 7361700000.00 0.00 0.00